{
    "clinical_study": {
        "@rank": "50119", 
        "arm_group": [
            {
                "arm_group_label": "Chemotherapy", 
                "description": "Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles."
            }, 
            {
                "arm_group_label": "Icotinib+Chemotherapy", 
                "description": "Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles."
            }
        ], 
        "brief_summary": {
            "textblock": "This phase II randomised, double blind, placebo controlled, multicentre trial is designed to\n      assess the efficacy and safety of continuous icotinib plus  chemotherapy versus chemotherapy\n      alone in patients who have progressed after benefiting from previous second or third-line\n      icotinib treatment (more than 6 months) in locally advanced or metastatic non-small cell\n      lung cancer."
        }, 
        "brief_title": "Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed stage IIIB/IV lung cancer(exclude patients\n             confirmed by sputum cytology)\n\n          -  No previous targeted treatment such as gefitinib, erlotinib.\n\n          -  With a measurable disease(longest diameters >=10mm with Spiral computed tomography\n             (CT)and >=20mm with conventional CT) according to RECIST Criteria\n\n          -  WHO performance status(PS)<= 2\n\n          -  N>=1.5\u00d7109/L, Plt>=1.0\u00d7109/L,Hb>=10g/dL;AST&ALT should <3ULN(without liver\n             metastasis) or <5ULN(with liver metastasis).TBIL<=1.5ULN.\n\n          -  Signed and dated informed consent before the start of specific protocol procedures.\n\n        Exclusion Criteria:\n\n          -  Allergic to icotinib\n\n          -  Patients with metastatic brain tumors with symptoms.\n\n          -  Experience of Anti-EGFR(the epidermal growth factor receptor) Monoclonal Antibody or\n             small molecular compounds therapy such as gefitinib, erlotinib or Cetuximab.\n\n          -  Severe systemic disease out of control such as unstable or uncompensated\n             respiratory,cardiac,liver,renal diseases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Study population in this trial aims to patients who have benefited from previous second or\n        third-line icotinib treatment (more than 6 months) in locally advanced or metastatic\n        non-small cell lung cancer and have progressed."
            }
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01707329", 
            "org_study_id": "BD-IC-IV44"
        }, 
        "intervention": [
            {
                "arm_group_label": "Chemotherapy", 
                "description": "Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.", 
                "intervention_name": "Chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Taxotere", 
                    "ALIMTA"
                ]
            }, 
            {
                "arm_group_label": "Icotinib+Chemotherapy", 
                "description": "Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.", 
                "intervention_name": "Icotinib+chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Icotinib", 
                    "Comana", 
                    "BPI-2009"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 19, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "state": "Hunan", 
                        "zip": "410205"
                    }, 
                    "name": "Hunan Province Tumor Hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "zyp@medmail.com.cn", 
                    "last_name": "Zhang Yi Ping, M.D.", 
                    "phone": "0086-13750881678"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310000"
                    }, 
                    "name": "Zhejiang Cancer Hospital"
                }, 
                "investigator": {
                    "last_name": "Zhang Yi Ping, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310000"
                    }, 
                    "name": "The First Affiliated Hospital of Medical School of Zhejiang University"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310000"
                    }, 
                    "name": "The Second Affiliated Hospital of Zhejiang University School of Medicine"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310000"
                    }, 
                    "name": "Sir Run Run Shaw Hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wenzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "325000"
                    }, 
                    "name": "The First Affiliated Hospital of Wenzhou Medical College"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "2", 
        "official_title": "A Phase II Randomised, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Who Have Progressed After Icotinib Treatment in NSCLC", 
        "overall_contact": {
            "email": "zyp@medmail.com.cn", 
            "last_name": "Zhang Yi Ping, MD", 
            "phone": "0086-13750881678"
        }, 
        "overall_official": {
            "affiliation": "Zhejiang Cancer Hospital", 
            "last_name": "Zhang Yi Ping, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A duration from randomization date to disease progression(as defined by RECIST) or death. If a participant\nare known to have progressed, the time to progression is defined as the time from the date of randomization to the date of progression. Otherwise, a  participant will be censored at the last date they are known not to be progressed.", 
            "measure": "Progression Free Survival", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01707329"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Overall Survival is assessed via calculation of the time to death due to any cause. If a participant is known to have died, the time to death is defined as the time from the date of randomization to the date of death. Otherwise, a participant will be censored at the last date they are known to be alive.", 
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Betta Pharmaceuticals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Betta Pharmaceuticals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}